Meeker David P
President and CEO at RYTM; Director at TRVI; ExecVP,Chief Operating Officer at GENZYME CORP
- Sold, on record
- $13.2M
- Dollars the filings state
- Form 4 sales
- 10
- Latest Sep 14, 2026
- Form 144 notices
- 0
- Proposed sales
- Companies
- 3
- Filed as an executive or holder
Companies
- RYTMRHYTHM PHARMACEUTICALS, INC.President and CEO
- TRVITrevi Therapeutics, Inc.Director
- GENZYME CORPExecVP,Chief Operating Officer
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- RYTM157,649 shares
- GENZYME CORP37,010 shares
- TRVI4,555 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale GENZYME CORPPlan not statedMay 25 2010
Sold 2,732 shares at $45.60 ($125k)
Meeker David P, ExecVP,Chief Operating Officer
Sold 21.4% of holdings ($583k position)10,045 shares leftFiling
- 2 Form 4 sale RYTMNo planFeb 1 +5000 days
Sold 4,361 shares at $45.06 ($197k)
Meeker David P, President and CEO
No 10b5-1 planSold 3.5% of holdings ($5.7M position)121,099 shares leftFirst sale on recordFiling
- 3 Form 4 sale RYTMNo planMar 19 +47 days
Sold 45,494 shares at $39.22 ($1.8M)
Meeker David P, President and CEO
No 10b5-1 planSold 20.7% of holdings ($8.6M position)174,605 shares leftFiling
- 4 Form 4 sale TRVINo planAug 27 +161 days
Sold 4,555 shares at $2.93 ($13k)
Meeker David P, Director
No 10b5-1 planSold 1.3% of holdings ($1M position)352,489 shares leftFirst sale on recordFiling
- 5 Form 4 sale RYTMNo planFeb 4 +161 days
Sold 4,278 shares at $59.43 ($254k)
Meeker David P, President and CEO
No 10b5-1 planSold 2.2% of holdings ($11.5M position)189,927 shares leftFiling
- 6 Form 4 sale RYTMRoutineFeb 19 +15 days
Sold 9,896 shares at $57.22 ($566k)
Meeker David P, President and CEO
10b5-1 planSold 4.7% of holdings ($12.1M position)201,281 shares left2.3x usual sizeFiling
- 7 Form 4 sale RYTMUnusualJun 3 +104 days
Sold 43,620 shares at $65.04 ($2.8M)
Meeker David P, President and CEO
10b5-1 planSold 17.8% of holdings ($16M position)201,825 shares left6.1x usual sizeFiling
- 8 Form 4 sale RYTMUnusualSep 14 +468 days
Sold 50,000 shares at $102.67 ($5.1M)
Meeker David P, President and CEO
10b5-1 planSold 17.3% of holdings ($29.7M position)239,258 shares left5.1x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (10)
| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | RYTM | President and CEO | Form 4 sale | 50,000 | $5.1M | 17.3% | Unusual | SEC |
| Jun 3, 2025 | RYTM | President and CEO | Form 4 sale | 43,620 | $2.8M | 17.8% | Unusual | SEC |
| Feb 19, 2025 | RYTM | President and CEO | Form 4 sale | 9,896 | $566k | 4.7% | Routine | SEC |
| Feb 4, 2025 | RYTM | President and CEO | Form 4 sale | 4,278 | $254k | 2.2% | No plan | SEC |
| Aug 27, 2024 | TRVI | Director | Form 4 sale | 4,555 | $13k | 1.3% | No plan | SEC |
| Mar 19, 2024 | RYTM | President and CEO | Form 4 sale | 45,494 | $1.8M | 20.7% | No plan | SEC |
| Feb 1, 2024 | RYTM | President and CEO | Form 4 sale | 4,361 | $197k | 3.5% | No plan | SEC |
| May 25, 2010 | GENZYME CORP | ExecVP,Chief Operating Officer | Form 4 sale | 2,732 | $125k | 21.4% | Plan not stated | SEC |
| May 21, 2010 | GENZYME CORP | ExecVP,Chief Operating Officer | Form 4 sale | 16,488 | $809k | 77.8% | Unusual | SEC |
| Aug 15, 2008 | GENZYME CORP | President LSD Therapeutics | Form 4 sale | 17,790 | $1.5M | 90.4% | Unusual | SEC |